Clinical trials: Primary Headache
Migraine Headache, Migraine
Neuro-Complex & Multi Supplements for Migraine Prevention
The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi…
- Conditions
- Migraine Headache, Migraine, Migraine in Adults
- Trial name
- NeuroCare (NCT07015411)
- Testing
- Neuro-Complex and Multi
- Where
- Belgium
- Volunteers
- 120 people
- Sponsor
- Benfida, a department of Handi-Move
Migraine
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
The purpose of this study is to learn about the effects of Rimegepant to help prevent migraine. This study is seeking for participants who: Are male and female of 18 years of age or older.
- Trial name
- NCT05810038
- Testing
- Rimegepant
- Where
- 49 sites in China
- Volunteers
- 787 people
- Sponsor
- Pfizer
Migraine
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
- Trial name
- NCT04804033
- Testing
- BHV-3500 (zavegepant)
- Where
- 116 sites in United States
- Volunteers
- 1,753 people
- Sponsor
- Pfizer
Episodic Cluster Headache
R-Verapamil for the Prophylaxis of Episodic Cluster Headache
This is a double-blinded, randomized, parallel, placebo-controlled phase 2 study to evaluate the safety and efficacy of R-verapamil in the prophylaxis of episodic cluster headache.
- Trial name
- NCT02209155
- Testing
- R-verapamil 75 mg tablet
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Center Laboratories, Inc.
Cluster Headache
Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
The primary objectives of the Registry are to: 1. Monitor the transfer of the ATI Neurostimulation System and its safety/clinical performance to a larger number of centers in the post market phase and 2.
- Trial name
- NCT01677026
- Where
- 11 sites in Denmark, Germany
- Volunteers
- 150 people
- Sponsor
- Autonomic Technologies, Inc.
Migraine
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
- Trial name
- NCT03670810
- Testing
- Lasmiditan
- Where
- 141 sites in United States, Austria and 15 more
- Volunteers
- 1,633 people
- Sponsor
- Eli Lilly and Company
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
The purpose of this study is to determine whether a fixed-dose combination of naratriptan + naproxen is effective compared each monotherapy for the acute treatment of migraine.
- Trial name
- Atenéia (NCT01390324)
- Testing
- Fixed-dose combination of naratriptan+naproxen, Naratriptan, Naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Chronic Migraine, Chronic Migraine, Headache
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with…
- Conditions
- Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
- Trial name
- PREVENTION (NCT05679908)
- Testing
- TNX-1900
- Where
- 26 sites in United States
- Volunteers
- 88 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Migraine
A Study of Prophylaxis for Migraine Patients With Topiramate in India
The purpose of this study is to evaluate the safety and effectiveness of topiramate in preventing migraine among Indian participants requiring prophylaxis (measure taken to maintain health and prevent the spread of disease).
- Trial name
- PROMPT-IN (NCT01836874)
- Testing
- No intervention
- Volunteers
- 209 people
- Sponsor
- Janssen-Cilag Ltd.
Migraine
A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) 12.5 milligram tablets compared with placebo for the acute treatment of migraine headache at the earliest onset of headache…
- Trial name
- NCT00210509
- Testing
- almotriptan malate
- Volunteers
- 378 people
- Sponsor
- Janssen-Ortho LLC
Migraine
Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects
The primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of AMG 333 for 14 days in healthy subjects and migraine subjects.
- Trial name
- NCT02132429
- Testing
- AMG 333
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine
Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches
In this open-label, multi-center study, patients were treated with frovatriptan for a maximum of 12 perimenstrual periods (PMPs).
- Trial name
- MAM (NCT01035983)
- Testing
- Frovatriptan 2.5 mg
- Where
- 5 sites in Germany, Hungary and 3 more
- Volunteers
- 550 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Migraine
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
- Trial name
- NCT02621931
- Testing
- Fremanezumab
- Where
- 273 sites in United States, Canada and 7 more
- Volunteers
- 1,130 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Headache, Tension-Type
Paracetamol With Caffeine to Treat Episodic Tension Type Headache
This study will compare a fast-absorbing paracetamol plus caffeine formula with placebo and an over-the-counter dose of paracetamol and ibuprofen to treat episodic tension headache.
- Trial name
- NCT01755702
- Testing
- Experimental paracetamol + caffeine formulation, ibuprofen marketed formulation, Paracetamol marketed formulation
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Migraine
A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis : a Prospective Observational Study
Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and…
- Trial name
- NCT02901756
- Testing
- Antemig
- Volunteers
- 132 people
- Sponsor
- PiLeJe
Migraine
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
- Trial name
- NCT02542605
- Testing
- Erenumab, PACAP-38 Challenge Agent
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 35 people
- Sponsor
- Amgen
Migraine
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
- Trial name
- UBR Prodrome (NCT04492020)
- Testing
- Ubrogepant 100 mg
- Where
- 73 sites in United States
- Volunteers
- 518 people
- Sponsor
- AbbVie
Migraine Disorders
Special Drug Use Investigation for AMERGE® Tablet (Long-term)
To investigate the long-term safety and efficacy of AMERGE (naratriptan hydrochloride) on Japanese patients with migraine headache in clinical setting
- Trial name
- NCT01332383
- Testing
- Naratriptan
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Migraine, Episodic Migraine
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Trial name
- NCT06004388
- Testing
- Click Digital Therapeutic
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Click Therapeutics, Inc.
Migraine
AMG 334 20160172 Pediatric Migraine PK Study.
AMG 334 20160172 Pediatric Migraine PK Study.
- Trial name
- NCT03499119
- Testing
- AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
- Where
- 14 sites in United States
- Volunteers
- 53 people
- Sponsor
- Amgen